Literature DB >> 7138562

Inhibitory effect of tranylcypromine on hepatic drug metabolism in the rat.

P M Bélanger, A Atitśe-Gbeassor.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7138562     DOI: 10.1016/0006-2952(82)90719-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  6 in total

Review 1.  Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.

Authors:  G B Baker; R T Coutts; K F McKenna; R L Sherry-McKenna
Journal:  J Psychiatry Neurosci       Date:  1992-11       Impact factor: 6.186

2.  An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

Authors:  Thomas M Polasek; David J Elliot; Andrew A Somogyi; Elizabeth M J Gillam; Benjamin C Lewis; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

3.  Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.

Authors:  Joo-Youn Cho; Kyung-Sang Yu; In-Jin Jang; Byung-Hwan Yang; Sang-Goo Shin; Dong-Seok Yim
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 5.  Metabolism of monoamine oxidase inhibitors.

Authors:  G B Baker; L J Urichuk; K F McKenna; S H Kennedy
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

6.  Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.

Authors:  Mahnaz Salsali; Andrew Holt; Glen B Baker
Journal:  Cell Mol Neurobiol       Date:  2004-02       Impact factor: 5.046

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.